Comparative Study of TIS Efficacy Across Different Targets

NCT07745673 | Recruiting

• 1 other identifier: linyanlun2025267
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective, randomized, participant- and outcome-assessor-blinded, parallel-group exploratory trial will compare the target-dependent clinical, neuroimaging, and electrophysiological effects of temporal interference stimulation (TIS) targeting the subthalamic nucleus (STN) or globus pallidus internus (GPi) in patients with Parkinson's disease (PD). Eighteen participants with idiopathic PD will be randomly assigned in a 1:1 ratio to the STN-TIS or GPi-TIS group. Participants will receive one 20-minute TIS session daily for 7 consecutive days. Motor symptoms will be assessed using the MDS-UPDRS Part III immediately before and after each daily stimulation session. Resting-state functional magnetic resonance imaging (fMRI) and 64-channel electroencephalography (EEG) will be performed before the first stimulation session and immediately after completion of the 7-day intervention. The primary outcomes are: (1) change in MDS-UPDRS Part III score from Day 1 before stimulation to Day 7 after stimulation; and (2) changes in regional spontaneous brain activity and seed-based functional connectivity measured using resting-state fMRI. Secondary outcomes are: (1) daily immediate changes in MDS-UPDRS Part III scores and the proportion of participants achieving at least 30% improvement at Day 7; and (2) changes in resting-state 64-channel EEG relative bandpower. Safety and tolerability will be evaluated by monitoring adverse events and local skin reactions throughout the intervention. This study aims to provide preliminary evidence regarding target-dependent functional response patterns associated with STN- and GPi-targeted TIS in PD.

Conditions

PARKINSON DIS

Keywords

Temporal Interference Stimulation; Parkinson's disease; Non-invasive deep brain stimulation; Randomized controlled trial

Outcome Measures

Primary Outcomes (2)

• Changes in motor symptoms in PD patients

  Motor symptoms will be assessed using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS Part III). All assessments will be conducted after withdrawal of antiparkinsonian medications for at least 12 hours. The change score will be calculated as the MDS-UPDRS Part III score immediately after the final stimulation session on Day 7 minus the score immediately before the first stimulation session on Day 1. A negative change value indicates improvement in motor symptoms.

  Immediately before the first stimulation session on Day 1 and immediately after the final stimulation session on Day 7.

• Changes From Baseline in Regional Spontaneous Brain Activity and Seed-Based Functional Connectivity After 7 Days of TIS

  Regional spontaneous brain activity and functional connectivity will be assessed using resting-state functional magnetic resonance imaging. Regional spontaneous brain activity will be evaluated primarily using the standardized amplitude of low-frequency fluctuation (zALFF). Seed-based functional connectivity will be calculated using predefined subthalamic nucleus and globus pallidus internus seed regions, and correlation coefficients will be transformed to Fisher z values. For each imaging measure, the change value will be calculated as the post-intervention value minus the baseline value. Within-group changes and between-group differences will be evaluated to characterize stimulation-related and target-dependent brain functional response patterns.

  Baseline before the first stimulation session and immediately after completion of the 7-day intervention.

Secondary Outcomes (2)

• Immediate Changes in MDS-UPDRS Part III Scores and Clinical Response Rate During the 7-Day TIS Intervention

  Immediately before and immediately after each stimulation session on Days 1 through 7; response rate assessed from immediately before the first stimulation session on Day 1 to immediately after the final stimulation session on Day 7.

• Change From Baseline in Resting-State 64-Channel EEG Relative Bandpower After 7 Days of TIS

  Baseline before the first stimulation session and immediately after completion of the 7-day intervention.

Study Arms (2)

Group A

EXPERIMENTAL

Stimulation target: subthalamic nucleus (frequency difference = 130 Hz), stimulation duration: 20 minutes, with 30-second ramp-up at the beginning and 30-second ramp-down at the end. All four stimulation impedances must be maintained at ≤10 KΩ. Duration: 7 consecutive days.

Device: TIS-STN

Group B

ACTIVE COMPARATOR

Stimulation target: globus pallidus (frequency difference = 130 Hz), stimulation duration: 20 minutes, with 30-second ramp-up at the beginning and 30-second ramp-down at the end. All four stimulation impedances must be maintained at ≤10 KΩ. Duration: 7 consecutive days.

Device: TIS-GP

Interventions

TIS-STN DEVICE

TIS stimulation target is the subthalamic nucleus (STN) , with a current intensity of 2 mA, base frequency of 2000 Hz, frequency difference of 130 Hz, and stimulation duration of 20 minutes.

Group A

TIS-GP DEVICE

TIS stimulation target is the globus pallidus (GP), with a current intensity of 2 mA, base frequency of 2000 Hz, frequency difference of 130 Hz, and stimulation duration of 20 minutes.

Group B

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult males or females aged ≥40 years;
• Diagnosis of idiopathic Parkinson's disease according to the UK Brain Bank criteria, with age of onset ≥40 years;
• Previous or current treatment with dopamine replacement therapy (e.g., levodopa) with good response;
• Hoehn and Yahr (H\&Y) stage 1.5-2.5;
• Able to walk independently for at least 5 minutes without assistive devices;
• No severe freezing of gait (FOG);
• Disease duration ≥2 years since diagnosis, clinically stable, and able to comply with study assessments and interventions;
• Stable medication regimen for at least 4 weeks prior to the study;
• Signed informed consent form; subject or legal guardian is able to understand and willing to participate in this study.

You may not qualify if:

• Presence of other neurological disorders that may affect the study (e.g., ...);
• Mild cognitive impairment or above (MoCA ≤23);
• Orthopedic or other medical conditions that may affect gait or balance;
• Contraindications to MRI, such as claustrophobia;
• History of antipsychotic, antidepressant, or other medications that may affect dopamine levels;
• History of other severe psychiatric disorders;
• History of epilepsy, traumatic brain injury, or implanted metallic devices in the brain or heart (e.g., stimulators, pacemakers) or other contraindications;
• History of electroconvulsive therapy (ECT);
• Currently participating in other gait- or balance-related intervention training;
• Physician-diagnosed cardiovascular risk factors for exercise.

Sponsors & Collaborators

• Zhongnan Hospital: lead

Study Sites (1)

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, 430071, China

RECRUITING

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Central Study Contacts

Yang Pan

CONTACT

13952098253; panyang.zn@whu.edu.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: chief Physician

Study Record Dates

• First Submitted: June 29, 2026
• First Posted: August 4, 2026
• Study Start: June 29, 2026
• Primary Completion (Estimated): January 31, 2027
• Study Completion (Estimated): December 31, 2027
• Last Updated: August 4, 2026

Record last verified: 2026-07

Locations

CN (1)